IP Library Granted Patent US 8,822,650
Granted Patent B2
US 8,822,650 · App. 13/087,593 · Granted Sep 2, 2014

Method for the mass production of immunoglobulin constant region

Inventors: Sung Youb Jung (Suwon-si, KR); Jin Sun Kim (Gwangmyeong-si, KR); Young Jin Park (Suwon-si, KR); Ki-Doo Choi (Seoul, KR); Se Chang Kwon (Seoul, KR); Gwan Sun Lee (Seoul, KR)
Assignee: Hanmi Science Co., Ltd
C07K16/46C07K2317/734C07K19/00A61K47/48507A61K47/48423C07K14/505C07K14/56C07K2319/30C07K2317/732C07K47/48415C07K14/61C07K14/535
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,822,650
App. No.
13/087,593
Granted
Sep 2, 2014
Kind
B2
Abstract

Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli -derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.

Claims (14)

1. A method of producing an immunoglobulin constant region, comprising:

(a) transforming an E. coli cell with a recombinant expression vector comprising (i) a nucleotide sequence encoding E. coli heat-stable enterotoxin II signal sequence and (ii) a nucleotide sequence encoding the immunoglobulin constant region without a variable region;

(b) culturing a resulting E. coli transformant in a medium; and

(c) isolating the immunoglobulin constant region expressed by the transformant, wherein the E. coli heat-stable enterotoxin II signal sequence is cleaved by a signal peptidase, and consists of the amino acid sequence of SEQ ID NO. 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46,

wherein the immunoglobulin constant region is expressed in the cytoplasm in a water soluble form and is not secreted into the medium or the periplasmic space.

2. The method according to claim 1 , wherein the immunoglobulin constant region is selected from the group consisting of constant regions from IgG, IgA, IgM, IgE, and IgD.

3. The method according to claim 2 , wherein the IgG is selected from the group consisting of constant regions from IgG1, IgG2, IgG3, and IgG4.

4. The method according to claim 3 , wherein the immunoglobulin constant region is an IgG4 constant region.

5. The method according to claim 4 , wherein the immunoglobulin constant region is a human aglycosylated IgG4 constant region.

6. The method according to claim 1 , wherein the immunoglobulin constant region is composed of one to three domains selected from the group consisting of CH1, CH2, CH3, and CH4 domains.

7. The method according to claim 6 , wherein the immunoglobulin constant region further comprises a hinge region.

8. The method according to claim 1 , wherein the recombinant expression vector comprises a nucleotide sequence encoding a heavy chain constant region and a nucleotide sequence encoding a light chain constant region.

9. The method according to claim 1 , wherein the immunoglobulin constant region has an amino acid sequence represented by SEQ ID NO. 21, 22, 23, 24, 25, 27, 29, 30, 34 or 35.

10. The method according to claim 1 , wherein the E. coli transformant is E. coli BL21/pSTIIG1CH1 — 3 (HM10935) of Accession No. KCCM-10600, BL21/pSTIIdCG1Fc (HM10927) of Accession No. KCCM-10588, BL21/pSTIIdCG1SFc (HM10928) of Accession No. KCCM-10589, BL21/pSTIIdCG1SFFc (HM10929) of Accession No. KCCM-10594, BL21/pSTIIG1Mo (HM10930) of Accession No. KCCM-10595, BL21/pSTIIdCG4Fc (HM10932) of Accession No. KCCM-10597, BL21/pSTIIG4-CH1 — 3 (HM10931) of Accession No. KCCM-10596, BL21/pSTIIG4Mo (HM10933) of Accession No. KCCM-10598, or BL21/pSTIIG4H_K (HM10934) of Accession No. KCCM-10599.

Assignments (1)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0341 →
Priority Claims (1)
KR 10-2003-0080299 · Nov 13, 2003 · national
Continuity (2)
Continuation 10535312
Related Publication 20110245472A1 · Oct 6, 2011